Royalty Pharma Announces Closing of Secondary Offering of Class A Ordinary Shares by Selling Shareholders
Royalty Pharma announced the closing of a secondary offering of 17,343,037 Class A ordinary shares at $42.00 per share. Proceeds from the sale will not benefit the company, as the shares were sold by existing shareholders. The SEC declared the registration statement effective on October 15, 2020. The offering was managed by major financial institutions including J.P. Morgan and Morgan Stanley. Royalty Pharma is a prominent buyer of biopharmaceutical royalties and funds innovation in the sector, holding royalties on over 45 commercial products.
- Successful completion of a secondary offering of 17,343,037 shares at $42.00 per share.
- Royalty Pharma has a diverse portfolio including royalties from over 45 commercial products, which could drive future revenue.
- The company did not receive any proceeds from the share sale, which could limit capital for operations.
NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today the closing of the secondary offering of 17,343,037 shares of its Class A ordinary shares by selling shareholders in an underwritten public offering at a price to the public of
J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs & Co. LLC and Citigroup acted as joint lead book-running managers and as representatives of the underwriters for the offering. Cowen, Evercore ISI, Truist Securities and UBS Investment Bank also acted as joint book-running managers for the offering. BBVA, DNB Markets, Scotiabank, TD Securities, Academy Securities, AmeriVet Securities, Blaylock Van, LLC, Cabrera Capital Markets LLC, R. Seelaus & Co., LLC, Ramirez & Co., Inc., Siebert Williams Shank and Tigress Financial Partners acted as co-managers for the offering.
A registration statement on Form S-1 relating to these securities was filed with, and on October 15, 2020 was declared effective by, the U.S. Securities and Exchange Commission (the “SEC”). The final prospectus relating to the public offering has been filed with the SEC and copies may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-866-803-9204 or by email at prospectus-eq_fi@jpmchase.com or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at prospectus@morganstanley.com. Copies of the registration statement and the final prospectus may also be accessed through the SEC’s website at www.sec.gov.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and three development-stage product candidates.
Forward-Looking Statements
This press release contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-0200
ir@royaltypharma.com
FAQ
What was the price of the secondary offering for RPRX shares?
How many shares were offered in the secondary offering for Royalty Pharma?
Did Royalty Pharma receive any proceeds from the secondary offering?
Who managed the secondary offering for RPRX?
What does Royalty Pharma do?
